Scrip
New life for ARYx's tecarfarin as US FDA approves development plans
07 January 2010
Asher Mullard
Please Login to read the full article.
07 January 2010
Asher Mullard
asher.mullard@informa.com
The US FDA has told ARYx Therapeutics that its existing development pathway is acceptable and will enable a filing of its vitamin K antagonising anticoagulant tecarfarin.
"Tecarfarin is being bought back onto the centre stage and is alive again,"
Dr Marko Kozul, an analyst at Jefferies,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck pipeline update: ESA development ditched because of regulatory hurdles
- Pharma rejects claims that it profited from H1N1 pandemic
- Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
- Russia sets priorities for national pharma industry
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
